STAT6d
Previewing Immunovant’s myasthenia gravis study readout — with all its quirky nuance
It’s show-me time for batoclimab, an antibody treatment from Immunovant and Roivant Sciences. Here's what you need to know.
WebMD2y
MG Is More Than Just General Fatigue
Welcome, everyone. I'm Dr. John Whyte, the Chief Medical Officer at WebMD. Today, I want to discuss myasthenia gravis. It's a rare autoimmune neuromuscular disease that causes weakness and fatigue ...
The American Journal of Managed Care13d
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent ...
WebMD2y
Treatment Goals With MG
I'm Dr. John Whyte, the Chief Medical Officer of WebMD. Today, I want to talk about a serious autoimmune condition called myasthenia gravis. It comes from the Latin and Greek which means grave ...
The American Journal of Managed Care4d
Phase 3 Data Support Nipocalimab for Myasthenia Gravis
The Vivacity-MG3 study is currently in its open-label extension phase, which is investigating the longer-term safety and ...
Immunovant’s Strategic Advancements and Market Potential Highlighted in Buy Rating
Analyst Brian Cheng of J.P. Morgan maintained a Buy rating on Immunovant (IMVT – Research Report), with a price target of $46.00.Invest with ...
Immunovant’s Promising Pipeline: Strategic Advances in FcRn Inhibitors and Market Expansion
Analyst Sam Slutsky of LifeSci Capital maintained a Buy rating on Immunovant (IMVT – Research Report), retaining the price target of ...